Thromboembolism

• CLINICAL_TRIALS withdrawal · 2022-11-14
  Clinical Trial Update: A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days [Phase 4]

  A Phase 4 trial investigating post-discharge Pradax for 10 days after total knee replacement was withdrawn.

• CLINICAL_TRIALS withdrawal · 2019-01-22
  Clinical Trial Update: Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury [Phase 4]

  A Phase 4 clinical trial assessing rivaroxaban absorption in patients with cervical spinal cord injury has been withdrawn.

• EMA withdrawal · 2012-07-27
  EMA Withdrawn: Refludan (lepirudin) — Celgene Europe Ltd.

  EMA withdrew Refludan (lepirudin) from the market in 2012, with thromboembolism and thrombocytopenia as therapeutic areas.